cryptoadam
Banned
UPMC, Pitt scientists unveil potential COVID-19 vaccine
Scientists with the University of Pittsburgh School of Medicine have announced a potential vaccine against COVID-19. Scientists say they’ve tested the vaccine in mice, and it produced antibodies specific to SARS-CoV-2 at quantities they believe could be enough to neutralize the coronavirus.
wjactv.com
Scientists with the University of Pittsburgh School of Medicine have announced a potential vaccine against COVID-19.
Scientists say they’ve tested the vaccine in mice, and it produced antibodies specific to SARS-CoV-2 at quantities they believe could be enough to neutralize the coronavirus.
The paper, which appeared in EBioMedicine, is the first study to be published after critique from scientists at outside institutions that identifies a possible vaccine for COVID-19, health officials said.
“We had previous experience on SARS-CoV in 2003 and MERS-CoV in 2014. These two viruses, which are closely related to SARS-CoV-2, teach us that a particular protein, called a spike protein, is important for inducing immunity against the virus. We knew exactly where to fight this new virus,” said co-senior author Andrea Gambotto, M.D., associate professor of surgery at the Pitt School of Medicine. “That’s why it’s important to fund vaccine research. You never know where the next pandemic will come from.”
“Our ability to rapidly develop this vaccine was a result of scientists with expertise in diverse areas of research working together with a common goal,” said co-senior author Louis Falo, M.D., Ph.D., professor and chair of dermatology at Pitt’s School of Medicine and UPMC.
Scientists say they’re calling the vaccine PittCoVacc, which is short for Pittsburgh Coronavirus Vaccine.
The vaccine works the same as a flu shot, scientists say, using lab-made pieces of viral protein to build immunity.
When tested in mice, PittCoVacc created a surge of antibodies against SARS-CoV-2 within two weeks of receiving the treatment, scientists say.
Those have not been tracked long term yet.
Scientists say they are now in the process of applying for an investigational new drug approval from the U.S. Food and Drug Administration and hope to starting a phase I human clinical trial in the next few months.
“Testing in patients would typically require at least a year and probably longer,” Falo said. “This particular situation is different from anything we’ve ever seen, so we don’t know how long the clinical development process will take. Recently announced revisions to the normal processes suggest we may be able to advance this faster.”